Related Experiment Video

Updated: May 20, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma

Masaomi Ikeda1, Tetsuo Fujita, Sumiyuki Mii

  • 1Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 252-0374, Japan. ikeda.masaomi@grape.plala.or.jp

Japanese Journal of Clinical Oncology
|July 12, 2012
PubMed
Abstract

Insights

Sorafenib can cause erythema multiforme in metastatic renal cell carcinoma patients. This study found it occurred in 25% of Japanese patients, necessitating careful monitoring and dermatologist consultation.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Sorafenib is a standard treatment for metastatic renal cell carcinoma (mRCC).
  • Sorafenib-induced erythema multiforme (EM) is considered rare.
  • This study investigates the incidence and characteristics of sorafenib-induced EM in mRCC patients.

Purpose of the Study:

  • To evaluate the occurrence of erythema multiforme in patients treated with sorafenib for metastatic renal cell carcinoma.
  • To assess the incidence and clinical presentation of sorafenib-induced EM.

Main Methods:

  • A cohort of 36 patients with mRCC treated with sorafenib (200-400 mg twice daily) from 2006-2011 was studied.
  • Skin biopsies were performed for patients with rash or EM, with histopathological confirmation.
  • Patch testing with sorafenib was conducted for patients diagnosed with EM.

Main Results:

  • A significant proportion of patients (78%) experienced skin reactions.
  • Erythema multiforme occurred in 9 out of 36 patients (25%).
  • All nine patients with EM showed a positive reaction to sorafenib on patch testing.

Conclusions:

  • Sorafenib-induced erythema multiforme may be more common than previously thought, particularly in Japanese patients.
  • Patients who develop EM while on sorafenib should not be retreated with the drug.
  • Close monitoring and dermatological consultation are crucial for managing sorafenib-induced skin toxicities.

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...